The AI in neurosurgery market was valued at USD 850 million in 2025 and is forecast to reach about USD 11.3 billion by 2035, expanding at a compound annual growth rate (CAGR) of 29.5% from 2026 to 2035, according to Acumen Research and Consulting. North America holds the largest share today, while Asia-Pacific is set to grow fastest.
Few specialties leave less room for error. A neurosurgeon working near the motor cortex or a brainstem tumour measures success in millimetres, and the brain itself shifts once the skull is opened. That is exactly why artificial intelligence is finding a home here faster than in many other surgical fields. Below, we unpack what is driving the market, which companies are shaping it, where adoption is concentrated, and what still holds the technology back.
AI in Neurosurgery Market at a Glance
| Indicator | Figure |
|---|---|
| Market value, 2025 | USD 850 million |
| Forecast value, 2035 | USD 11,300.43 million |
| CAGR, 2026 to 2035 | 29.5% |
| Leading region | North America (46.0% share in 2025) |
| Fastest-growing region | Asia-Pacific (34.2% CAGR) |
| Largest component | Software (57.0%) |
| Largest procedure segment | Neuro-oncology surgery (26.0%) |
Data: Acumen Research and Consulting, AI in Neurosurgery Market report, updated 1 October 2026.
Why Neurosurgery Is Fertile Ground for AI
Neurosurgery runs on images. Almost every decision, from whether to operate to where to place the first incision, starts with an MRI or CT scan. That gives AI a rich, structured input to learn from. Machine learning models can outline a glioma, flag a small aneurysm or measure a bleed far faster than a human can do by hand, and they do it the same way every time.
The second reason is complexity. Patients differ in anatomy, tumour biology and vascular structure. AI tools that turn scans into patient-specific 3D models let surgical teams rehearse an approach before they ever enter the theatre. Add robotics and navigation systems that already sit in many neurosurgical suites, and the infrastructure for AI is largely in place.
What Is Driving Growth in the AI in Neurosurgery Market?
Imaging is the gateway application
MRI accounted for 34.0% of the market by imaging modality in 2025, followed by CT at 24.0% and multimodal or fusion imaging at 18.0%. Diagnosis and preoperative assessment was the largest application, at 21.0%. In other words, most hospitals meet neurosurgical AI first as a reading and triage tool, and only later bring it into the operating room. Stroke care is a good example: in the UK, AI-assisted brain scan analysis now supports every stroke unit in England.
Brain tumours lead the way
Neuro-oncology surgery held a 26.0% share in 2025, ahead of spine and spinal cord surgery (22.0%) and cerebrovascular surgery (16.0%). Tumour surgery combines everything AI does well: segmentation, margin estimation, and the prediction of how much tissue can be removed safely. It is also where research is most active. A review of 193 studies cited by Acumen found that just over half focused on diagnostic AI in neuro-oncology.
Software is where the value sits
Software made up 57.0% of the market in 2025, well ahead of hardware (29.0%) and services (14.0%). Machine learning and deep learning accounted for 43.0% of the technology mix, computer vision for 29.0% and generative AI for 12.0%. For buyers, this is good news. A hospital that already owns a navigation system or a surgical robot can often add AI through a software licence rather than a new capital project.
Hybrid deployment is gaining momentum
On-premise systems still dominate with a 48.0% share, which makes sense when sensitive brain imaging and real-time operating room data are involved. Even so, hybrid deployment is the fastest-growing model, with a projected CAGR of 32.2%. Keeping time-critical processing on site while using the cloud for model updates and analytics suits large hospital networks well.
Navigation, robotics and brain-computer interfaces are converging
The line between imaging, navigation and robotics is blurring. In January 2026, Precision Neuroscience and Medtronic announced a partnership to integrate Precision’s Layer 7 brain-computer interface with the StealthStation navigation platform. Earlier, in June 2025, Johnson & Johnson MedTech launched the Polyphonic AI Fund for Surgery with NVIDIA and Amazon Web Services, backed by a survey in which nearly 95% of healthcare professionals supported greater AI integration. Deals like these suggest the next generation of neurosurgical platforms will be built around data from the start.
A Reality Check: Strong Accuracy, Thin Validation
The research numbers tell two stories at once. Diagnostic AI models in neurosurgery report median accuracies above 85% across most categories, which is impressive. Yet only 22.6% of studies tested their models on external data, just 7.1% made an application publicly available, and roughly 20% shared their code.
From a clinical perspective, that gap matters more than the headline accuracy. A model that performs well on one hospital’s scanners may falter on another’s, or on a patient population it has never seen. Neurosurgical teams evaluating AI tools should ask for evidence from multiple centres, clear information on how the model was trained, and a plan for monitoring performance once it goes live. Vendors that can answer those questions convincingly will win long-term trust; those that cannot will struggle to move beyond pilots.
What Does Neurosurgical AI Infrastructure Cost?
Cost remains one of the biggest brakes on adoption, especially outside major academic centres. Acumen’s report outlines typical price ranges for the technology that AI tools often run on or alongside:
| Technology | Typical cost |
|---|---|
| Neuronavigation infrastructure | USD 150,000 to 400,000 |
| Cart-based intraoperative ultrasound | USD 50,000 to 200,000 |
| Neurosurgical ultrasound probes | About USD 10,000 to 30,000 |
| Stimulated Raman histology platforms | About USD 400,000 to 500,000 |
| Intraoperative MRI infrastructure | USD 1 million to 10 million |
| Augmented-reality head-mounted display | About USD 3,500 |
The spread is wide. An AR headset costs less than many surgical instruments, while an intraoperative MRI suite is a major capital decision. This is one reason software-based AI, which can sit on top of existing equipment, is growing so quickly.
Leading Companies in the AI in Neurosurgery Market
The competitive landscape blends large medical technology groups with specialist innovators. Acumen Research and Consulting lists the following companies among the key players:
| Company | Headquarters | Role in neurosurgical AI |
|---|---|---|
| Medtronic | United States (operational) | StealthStation navigation and robotic systems |
| Brainlab | Munich, Germany | Image-guided surgery and planning platforms |
| Zimmer Biomet | United States | Surgical robotics |
| Stryker | United States | Neurosurgical and navigation technologies |
| Intuitive Surgical | United States | Robotic surgery systems |
| Synaptive Medical | Toronto, Canada | Surgical planning and visualisation |
| Precision Neuroscience | United States | Brain-computer interfaces |
| Accuray | United States | Robotic radiosurgery |
| Globus Medical | United States | Spine and neurosurgical devices |
| Siemens Healthineers | Erlangen, Germany | AI-enabled medical imaging |
Two patterns stand out. Established players such as Medtronic, Brainlab and Stryker are layering AI onto navigation systems already installed in thousands of hospitals. Meanwhile, newer firms like Precision Neuroscience and Synaptive are pushing into brain-computer interfaces and advanced visualisation, often by partnering with the incumbents rather than competing head-on.
Which Region Leads the AI in Neurosurgery Market?
North America leads the AI in neurosurgery market, with a 46.0% share in 2025. The region also has the highest concentration of providers: eight of the ten key companies identified by Acumen are based in the United States or Canada. Strong reimbursement, a large installed base of navigation and robotic systems, and an active regulatory pathway all help. The US Food and Drug Administration has authorised more than 1,600 AI-enabled medical devices and has issued draft guidance specific to robotically assisted surgical devices.
How Do Regions Compare?
| Region | Position | What shapes adoption |
|---|---|---|
| North America | Largest (46.0% share, 2025) | Dense provider base, FDA pathway, established robotics and navigation |
| Asia-Pacific | Fastest-growing (34.2% CAGR) | Hospital investment, national industrial policy, ageing populations |
| Europe | Established and policy-driven | Public funding for AI, home to Brainlab and Siemens Healthineers |
| Rest of the world | Early stage | Private hospital groups and specialist centres |
Asia-Pacific: the growth engine
Asia-Pacific is expected to expand at a 34.2% CAGR between 2026 and 2035, faster than any other region. China’s medical products regulator has named high-end imaging devices, medical robots and AI medical equipment as development priorities, which is accelerating domestic innovation. Japan, regulated by the PMDA and the Ministry of Health, Labour and Welfare, pairs a mature robotics industry with the needs of a rapidly ageing population. India is an emerging opportunity too. Its large private hospital chains are investing in navigation and robotic programmes, and imaging-based AI, which needs less upfront capital, is a practical first step.
Europe: public investment meets strict oversight
Europe’s strengths are research depth and public funding. The UK has set up a National Commission on AI in Healthcare and has backed 86 AI technologies through its AI in Health and Care Awards. Germany is investing in AI living labs and sovereign health-data infrastructure, and is home to Brainlab and Siemens Healthineers. Adoption tends to be evidence-led, which slows early uptake but builds durable confidence.
Who Buys AI for Neurosurgery?
Hospitals accounted for 61.0% of demand in 2025, followed by specialty neurosurgery and neurology centres (17.0%) and academic and research medical centres (12.0%). Beyond diagnosis, the main uses inside the operating room are intraoperative navigation and guidance (19.0%) and surgical planning and simulation (18.0%). Expect the specialty-centre share to rise as software lowers the entry cost.
Challenges That Could Slow Adoption
- Limited external validation: Many models have not been tested across different hospitals, scanners and patient groups.
- High implementation costs: Navigation, intraoperative imaging and trained staff require significant investment.
- Regulatory complexity: AI that supports diagnosis or intraoperative decisions faces demanding approval and monitoring requirements.
- Data bias: Training data that under-represents some populations can weaken performance where it is needed most.
- Explainability and trust: Surgeons need to understand why a tool makes a recommendation before acting on it.
- Workflow integration: Tools must fit smoothly with imaging systems and electronic health records.
The Road to 2035
Over the next decade, three opportunities look most promising. AI-powered navigation that fuses preoperative imaging with real-time guidance will help correct for brain shift during surgery. AI-enhanced robotic systems will add automated image analysis and precision support. And remote neurosurgery platforms could extend specialist expertise to hospitals that lack it, which is particularly relevant for large countries with uneven access to neurosurgeons, India among them.
The market’s growth curve is steep, but its long-term winners will be decided by evidence, not hype. Tools that prove their value across diverse patients, explain their reasoning and fit naturally into the surgeon’s workflow are the ones likely to become standard of care. For a broader view of how AI is reshaping the operating room, see our analysis of the AI-assisted surgery market.
Frequently Asked Questions
What is the size of the AI in neurosurgery market?
The global AI in neurosurgery market was valued at USD 850 million in 2025 and is projected to reach USD 11,300.43 million by 2035, according to Acumen Research and Consulting.
How fast is the AI in neurosurgery market growing?
The market is expected to grow at a CAGR of 29.5% from 2026 to 2035.
Which region dominates the AI in neurosurgery market?
North America dominates with a 46.0% share in 2025. Asia-Pacific is the fastest-growing region, with a projected CAGR of 34.2%.
Who are the key players in the AI in neurosurgery market?
Key companies include Medtronic, Brainlab, Zimmer Biomet, Stryker, Intuitive Surgical, Synaptive Medical, Precision Neuroscience, Accuray, Globus Medical and Siemens Healthineers.
How is AI used in neurosurgery?
AI is used to analyse MRI and CT scans, support diagnosis and preoperative assessment, build patient-specific surgical plans, guide navigation during surgery and power robotic and brain-computer interface systems.
Which neurosurgical procedure uses AI the most?
Neuro-oncology (brain tumour) surgery is the largest segment, with a 26.0% share in 2025, followed by spine and spinal cord surgery at 22.0%.
Market figures are drawn from the AI in Neurosurgery Market report by Acumen Research and Consulting (last updated 1 October 2026). This article is for information only and does not constitute medical or investment advice.